Highlights

  • Healius Ltd (ASX:HLS) reported 1H26 group Revenue of $688.1 million, up 3.8% from the prior corresponding period.
  • Underlying EBITDA increased 13.1% to $122.2 million, while underlying EBIT improved to $7.9 million from a $2.7 million loss.
  • Pathology revenue rose 3.5% to $666.3 million, while Agilex revenue increased 16.0% to $21.8 million.
  • At the time of writing this article, Healius Ltd (ASX:HLS) was trading at AUD 0.418, up 3.09% during today’s trading session.

At the time of writing this article, Healius Ltd (ASX:HLS) was trading at AUD 0.418, up 3.09% during today’s trading session. Healius is an Australian healthcare company focused primarily on pathology services, supported by its Agilex Biolabs operations. The company provides specialty pathology services across Australia through a national network serving patients and referring practitioners. During 2026, Healius has continued working on revenue mix, cost management, pathology productivity and growth in areas including genomics and business-to-business services.

Company Business

Healius operates a national pathology Business providing diagnostic testing services across Australia. Its pathology operations include collection centres, laboratories and specialist diagnostic services supporting general practitioners, specialists, hospitals and other healthcare providers.

The company also owns Agilex Biolabs, a bioanalytical laboratory business supporting pharmaceutical and biotechnology customers. Agilex provides laboratory services associated with clinical development and drug research, giving Healius exposure to activities outside its core Medicare-linked pathology operations.

Healius has also been investing in digital systems across its pathology network, including laboratory and customer-facing technology intended to support operational processes, referral management and results delivery.

Recent Development

During September 2026, Healius Pathology Network released a population-level report examining cardiovascular and metabolic risk factors among Australian women. The report used pathology data to assess the prevalence of cardiometabolic abnormalities and highlighted differences associated with age and socioeconomic conditions.

Earlier in 2026, the company continued implementing its operational improvement program across pathology. The strategy has focused on adjusting the revenue mix, expanding specialist and non-Medicare revenue streams and improving labour productivity across collection centres and laboratories.

Healius also continued developing higher-value diagnostic areas. During the first half of FY26, management identified genomics, clinical trials, veterinary pathology and other business-to-business activities as contributors to revenue growth beyond Volume increases.

Agilex Biolabs also recorded increased activity during the half, with revenue and Earnings rising compared with the prior corresponding period.

Financial Performance and Sector Context

For the six months ended 31 December 2025, Healius reported group revenue of $688.1 million, representing a 3.8% increase from $662.6 million in the prior corresponding period.

Underlying EBITDA increased 13.1% to $122.2 million, while underlying EBIT improved to $7.9 million from a $2.7 million loss in 1H25. Reported EBIT was a loss of $12.9 million compared with a reported loss of $22.6 million a year earlier. Reported net profit after tax, including discontinued operations, was a loss of $30.4 million.

Pathology revenue increased 3.5% to $666.3 million. Pathology volumes increased 1.2% during the half, while average fees improved as the revenue mix shifted toward areas including genomics, Clinical Trials and veterinary pathology.

Agilex revenue increased 16.0% to $21.8 million, while EBITDA rose 65.5% to $4.8 million.

At the end of the first half, Healius reported net cash of $11.6 million.

The broader pathology sector remains influenced by testing volumes, Medicare settings, specialist referral activity and operating costs. Labour is a significant cost component for pathology providers, making workforce efficiency an important Factor in margins.

Risks to Consider

Healius remains exposed to changes in pathology volumes, Medicare funding settings and referral patterns across general practitioners and specialists. Regulatory changes affecting reimbursable tests may also influence testing activity.

Labour costs remain a material operating expense, and delays in productivity initiatives could affect Margin improvement. The business also faces execution risk as it implements cost reductions and technology changes across a large national laboratory and collection network.

Agilex is exposed to conditions in biotechnology and pharmaceutical research spending, where changes in project timing or funding can affect laboratory demand.

What to Watch Next

Investors may monitor the continued implementation of Healius’ cost and productivity program, including labour optimisation and support-cost reductions.

Pathology revenue mix will also remain important, particularly growth in genomics, specialist referrals, clinical trials and other non-Medicare activities.

Further updates from Agilex will provide information on whether the revenue growth recorded in 1H26 is sustained as pharmaceutical and biotechnology customers progress clinical development programs.

Healius is also scheduled to hold its 2026 Annual General Meeting in October, which may provide further commentary on operational priorities and progress against its broader transformation program.

Key Insights

Healius’ 2026 performance has reflected improving underlying profitability within its core pathology operations. First-half revenue increased, underlying EBITDA rose and underlying EBIT moved into positive territory compared with the previous corresponding period.

The company is continuing to focus on revenue diversification, labour productivity and operational efficiency while developing higher-value diagnostic services. Agilex also contributed higher revenue and EBITDA during the first half.

Future performance will depend on pathology volumes, revenue mix, cost execution and continued progress across specialist diagnostics and laboratory services.